Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

3:51pm IST
Change (% chg)

Rs21.45 (+2.32%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LUPN.BO


Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)


Beta: 0.00
Market Cap(Mil.): Rs417,143.91
Shares Outstanding(Mil.): 451.75
Dividend: 7.50
Yield (%): 0.81


  LUPN.BO Industry Sector
P/E (TTM): 20.57 30.66 31.86
EPS (TTM): 44.89 -- --
ROI: -- 14.54 14.08
ROE: -- 15.62 15.39

BRIEF-Lupin gets EIR from U.S. FDA for Aurangabad inspection

* Says receives EIR from U.S. FDA for Aurangabad, April 2017 inspection

21 Aug 2017

BRIEF-Natco Pharma says co, Lupin get FDA nod for generic lanthanum carbonate chewable tablets‍​

* Says Natco, Lupin get FDA nod for generic lanthanum carbonate chewable tablets‍​

14 Aug 2017

Sun Pharma reports first-quarter loss as generics business suffers

India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a surprise quarterly loss on Friday due to one-off legal costs and pressure over prices in its largest market, the United States, casting a shadow over its growth prospects.

11 Aug 2017

UPDATE 2-India's Sun Pharma reports Q1 loss as generics business suffers

* Expects profit margin to improve in second-half of 2018 (Adds Managing Director comments from conference call)

11 Aug 2017

BRIEF-Lupin appoints Manju Deshbandhu Gupta as chairman

* Says appoints Manju Deshbandhu Gupta as chairman Source text - http://bit.ly/2vLkapj Further company coverage:

11 Aug 2017

BRIEF-Lupin gets FDA nod for Nikita (pitavastatin) tablets

* Says Lupin receives FDA approval for Nikita (pitavastatin) tablets

09 Aug 2017

BRIEF-Lupin gets U.S. FDA approval for generic Crestor tablets

* Says approval for Rosuvastatin Calcium tablets 5 mg, 10 mg, 20 mg and 40 mg Source text - http://bit.ly/2w91bm3 Further company coverage:

03 Aug 2017

BRIEF-India's Lupin says expects to be back in strong growth in FY19 in North America

* CEO says co expects to be back in strong growth in fiscal year 2019 in North America

03 Aug 2017

Lupin first-quarter profit slumps, misses estimates

Drugmaker Lupin Ltd said on Wednesday first quarter profit fell 59 percent, well below analysts' estimates, as regulatory hurdles and pricing pressure in the United States, its biggest overseas market, weighed.

02 Aug 2017

UPDATE 1-India's Lupin Q1 profit slumps, misses estimates

* New nationwide tax in India, price erosion in U.S. weigh (Adds details, top exec comment, background)

02 Aug 2017

Earnings vs. Estimates